UK Leads in Laser Vision Correction
Contact: Jennifer Bonck
LEXINGTON, Ky. (Oct. 10, 2003) -- Sight is a precious gift. Unlike any other human ability or sense, vision is an integral and vital part of life.
Innovations in eye care technology are preserving this precious gift like never before.
The U.S. Food and Drug Administration (FDA) has approved a personalized eye laser treatment system, the Zyoptix™ system, manufactured by Bausch & Lomb, in the correction of near-sightedness and astigmatism. The University of Kentucky Department of Ophthalmology is one of the first in the region to acquire this technology to provide its patients with state-of-the-art care.
“Approximately 90 percent of individuals that need vision correction have myopia (near-sightedness) or astigmatism,” says John Conklin, M.D., associate professor of ophthalmology and director of the UK Refractive Surgery Service, UK College of Medicine. “We’re delighted to offer our patients a safe and effective alternative to glasses using the best personalized laser vision treatment technology available, and patients can be confident in this procedure.”
This confidence comes in the form of careful research into the effectiveness of the treatment. Multi-center clinical trials in the United States for FDA approval of Zyoptix™ generated impressive outcomes, including:
- 99.7 percent of patients said that their quality of vision was improved after treatment;
- 84.7 percent of patients expressed extreme improvement;
- 91.5 percent of patients said their vision was 20/20 or better after treatment; and
- 98.5 percent of patients were satisfied or extremely satisfied with the results.
“The clinical research clearly shows that the technology has the best patient visual outcomes determined by customer satisfaction,” says Conklin. “Not only were more than 98 percent of the patients satisfied or extremely satisfied six months after treatment, but no patients were dissatisfied and there were no re-treatments during that period – traditional LASIK surgery can’t say that.”
This laser eye technology is unique for a variety of reasons, which include the ability to change the diameter of the laser for more precision. It also has an advanced diagnostic system, which analyzes thousands of data points across the entire eye, to produce a personalized treatment plan. Success with this procedure has been proven abroad for over two years, with nearly 100,000 procedures in Europe and other parts of the world. FDA approval now makes it available in the United States.
For more information about this revolutionary procedure, call the UK Refractive Surgery Service, in the UK Department of Ophthalmology, at 859-323-5867.